Search results
Results from the WOW.Com Content Network
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, [2] [1] [3] employing approximately 5,400 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in ...
As a result of pressure from HIV-infected men in the gay community, [citation needed] who demanded better access to clinical trials, the U.S. Congress passed the Health Omnibus Programs Extension Act of 1988 (Public Law 100-607) [2] which mandated the development of a database of AIDS Clinical Trials Information Services (ACTIS). [3]
The DRKS is an open access, free of charge online register for clinical trials and is available both in English and German. DRKS is part of the WHO's ICTRP. The DRKS works with two partner registries in Germany, DeReG (German Registry for Somatic Gene-Transfer Trials) and Clinical Trial Registry of the University Medical Center Freiburg. [4]
In late 2012, Sophia’s Cure agreed to provide another $550,000 for a Phase 1 clinical trial. The Nationwide Children’s Hospital Foundation, an affiliate of the hospital, agreed to match it.
Short of joining a clinical trial with this team, it could be a while until people have access to this test. “There is no average timeline for clinical translation,” Bramen says.
The Michael J. Fox foundation does a range of other social experiments and interventions which interrelate to the platform and have the overall intent to make for better engagement between clinical trials and research participants. [4] The platform has experimented with conducting research participant study visits through remote video chat.
Some of these include the administration of cancer research programs, training activities, core facilities with technology shared by investigators, and clinical trial management services. [ 2 ] In 2015, more than 353,000 new patients were enrolled in a clinical trial at an NCI-designated Cancer Center.
The antibody treatment, sasanlimab, in combination with Bacillus Calmette-Guérin (BCG) vaccine met the main goal of the study in patients with high-risk non-muscle invasive bladder cancer (NMIBC ...